SCREEN for Type 1 Diabetes Act of 2026
SB 4612, the SCREEN for Type 1 Diabetes Act of 2026, would amend the Public Health Service Act to create a national, evidence-based public awareness campaign on type 1 diabetes detection, screening, and management. The campaign would be run by the Secretary of Health and Human Services through the CDC and would include publicly accessible written materials, public service announcements, and outreach through social media, television, radio, print, the internet, in-person or virtual communications, and trusted figures.
The bill also requires consultation with medical, public health, nonprofit, school, and higher education stakeholders to develop culturally and linguistically appropriate materials. It directs the campaign to focus on communities with the largest recent increases in type 1 diabetes incidence and to provide information to health care providers, public health departments, schools, and colleges. The bill authorizes $5 million annually for fiscal years 2027 through 2031 and requires a report to Congress within one year of enactment assessing the campaign and its impact on detection, screening, and management.
If enacted, the bill would expand federal public health activity under section 317H of the Public Health Service Act by replacing the existing subsection on type 1 diabetes with a more detailed national awareness and screening campaign. It would not create a new insurance benefit or mandate screening coverage, but it would direct HHS and CDC to develop educational materials, coordinate grants and cooperative agreements, and support state, local, and Tribal public health departments in increasing screening access and awareness. The bill would also impose a reporting requirement on HHS and authorize dedicated appropriations for the program.
The available context suggests generally favorable, bipartisan support for the bill’s public health goals, as reflected by introduction from Senator Shaheen with Senator Collins as a cosponsor. There are no recorded committee transcripts or votes in the provided material, so there is no evidence of formal opposition or amendment debate in the record supplied. The bill’s framing around evidence-based education, early detection, and support for affected communities indicates a consensus-oriented approach.
No specific points of contention are documented in the provided materials. Potential areas of policy discussion, based on the text, could include the scope of federal involvement in public awareness campaigns, how grant funds are allocated to states and nonprofits, and how the bill identifies and targets communities with rising incidence rates. Another possible issue is whether the authorized funding level and reporting requirements are sufficient to measure effectiveness and justify the program, but no stakeholder objections are recorded here.